UK Freephone Orders
0800 387732
9am to 5pm Mon-Fri
International Orders
+44 2380 487209
Select Your Country

Quantum Blue anti-TNFα Drug Monitoring

The Quantum Blue® Infliximab assay, from BÜHLMANN, is the first rapid test to measure this anti-inflammatory biologic drug trough level, in patient’s serum. It allows prompt decision making for dose adjustments before the next infliximab infusion.


Infliximab is a therapeutic monoclonal antibody. This anti-inflammatory biologic drug acts as an antagonist to TNF alpha. It is used to treat numerous chronic inflammatory diseases such as Crohn’s disease, ulcerative colitis and inflammatory arthritis and is effective in blocking the inflammatory process.

Monitoring anti-TNFα concentrations in patients is important as the level of response can vary between individuals and within the same person over time. Sub-therapeutic drug levels and the formation of anti-drug antibodies (ADAs) may decrease their efficacy.

Infliximab Trough Level

The therapy of chronic inflammatory diseases has improved enormously over the past two decades with the development of biologic anti-inflammatory drugs such as infliximab.  These drugs help to ameliorate disease course and keep inflammations at remission levels for prolonged periods of time.

However, administering the optimum dosage of infliximab, at the correct time, is important in achieving the best outcome for individual patient treatment. If a patient has low drug concentrations then they will have a poorer outcome than those with adequate drug levels. 

Thus, management of anti TNF therapy by therapeutic drug monitoring (TDM) has a great potential for improving patient responsiveness to these costly medicines.

Studies have shown that an adequate infliximab trough level can be determined in Crohn’s patients, helping to guide the treatment.  An optimal concentration window for trough level seems to be the range from 3 to 7 µg/ml of infliximab in serum.

Adapted from Casteele et al., Gastroenterology, 2015

The Quantum Blue® Infliximab is a rapid test that provides a quantitative result within 15 minutes of incubation time. It is ideal for use at point-of-care (POCT) and enables health care providers to check a patient's current drug level and act accordingly before infusion of the next infliximab dose. This supports optimisation of drug dosage for maximum effectiveness.

Quantum Blue® Infliximab is unique in the diagnostics market, being the only test that can provide fast, reliable TDM information for infliximab and correlating well with the standard routine ELISAs for determination of infliximab levels.

The assay measures from 0.4 to 20 µg/ml, and the target concentrations for trough level interpretation lies well within the linear range of the test.

  • Single use assay:
    • No need to batch samples
    • Individually packaged to ensure the quality of the assay required
  • Assay time of 15 minutes
  • Quantitative assay range of 0.4 - 20µg/ml
  • Excellent correlation with established ELISA methods
  • Control included on each cassette
  • Read using a simple bench top reader (about the size of a desk top telephone)

  • Patient-near Infliximab trough-level testing by a novel quantitative rapid test: The Quantum Blue Infliximab test

    • PDF size: 11.01KB
    • Uploaded on: 25/11/2016

    Lindsjø et al. Poster - UEG Week October 2016

    Open File
  • Performance of the BÜHLMANN Quantum Blue® Infliximab point-of-care assay dedicated for therapeutic drug monitoring of serum infliximab trough levels

    • PDF size: 12.37KB
    • Uploaded on: 23/08/2016

    ECCO, March 16-19, 2016, Poster No. 242

    Open File
  • Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays

    • PDF size: 9.51KB
    • Uploaded on: 05/10/2016

    Afonso J et al. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92

    Open File
  • Quantum Blue Infliximab Test

    • PDF size: 810.31KB
    • Uploaded on: 03/02/2017

    Product Flyer

    Open File

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Casteele, V et al. Gastroenterology. 2015 Jun;148(7)

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care
quantitative test with two established ELISA assays

Afonso J et al. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92

Set Descending Direction

1 Item(s)

Grid List